Compare CALX & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CALX | LGND |
|---|---|---|
| Founded | 1999 | 1987 |
| Country | United States | United States |
| Employees | N/A | 68 |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.7B |
| IPO Year | 2009 | N/A |
| Metric | CALX | LGND |
|---|---|---|
| Price | $43.47 | $219.83 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $66.50 | ★ $256.29 |
| AVG Volume (30 Days) | ★ 1.0M | 192.7K |
| Earning Date | 04-21-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 157.78 | N/A |
| EPS | ★ 0.16 | N/A |
| Revenue | ★ $510,367,000.00 | N/A |
| Revenue This Year | $16.40 | $1.25 |
| Revenue Next Year | $13.75 | $19.41 |
| P/E Ratio | $271.38 | ★ $76.27 |
| Revenue Growth | ★ 11.24 | N/A |
| 52 Week Low | $40.75 | $98.90 |
| 52 Week High | $71.22 | $247.38 |
| Indicator | CALX | LGND |
|---|---|---|
| Relative Strength Index (RSI) | 40.42 | 48.98 |
| Support Level | $40.75 | $180.85 |
| Resistance Level | $56.04 | $227.92 |
| Average True Range (ATR) | 2.10 | 10.66 |
| MACD | 0.11 | -2.19 |
| Stochastic Oscillator | 22.99 | 42.22 |
Calix Inc develops, markets and sells its appliance-based platform, cloud and managed services that enable service providers of all types and sizes to innovate and transform their businesses. The company's customers utilize the real-time data and insights from Calix platforms to simplify their business and deliver experiences that excite their subscribers. The resulting growth in subscriber acquisition, loyalty and revenue creates more value for their businesses and communities. The Company's revenue is principally derived in the United States and it also has its presence in Europe, Americas excluding U.S., and Rest of World.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.